CRISPR Therapeutics AG — Director's Dealing 2017

Dec 5, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2017-12-01

Reporting Person: Kulkarni Samarth (Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-12-01	Restricted Stock Units	A	26667	$19.12	Acquired	133560	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-12-01	Stock Option (Right to Buy)	$19.12	A	260000	Acquired	2027-12-01	Common Shares (260000)	Direct

Footnotes

F1: This option was granted on December 1, 2017 and shall vest in 48 equal monthly installments.